What is Canafenib/Encofenib (Betavi) and its clinical application

Canafenib (Encorafenib) is an oral BRAF kinase inhibitor that mainly targets tumors with BRAF V600 mutations. By specifically inhibiting the activity of mutant BRAFkinase and blocking the MAPK signaling pathway, it inhibits the proliferation and growth of tumor cells. As a new generation of BRAF inhibitors, Encorafenib has certain advantages in drug stability and drug resistance management. It also has high oral bioavailability, making daily treatment more convenient for patients.

Encorafenibis mainly used for the treatment of BRAF V600E or V600K mutation-positive melanoma, especially for patients with unresectable or metastatic disease. In addition to melanoma, some studies and clinical trials have also shown its potential efficacy in BRAF mutated colorectal cancer and other solid tumors. Clinically, this drug is often used in combination with MEK inhibitors (such as Binimetinib) to delay the development of drug resistance and improve efficacy.

Encorafenibcombined with MEK inhibitors to treat BRAF mutant tumors can significantly improve the objective response rate (ORR ), progression-free survival (PFS) and overall survival (OS), while reducing the incidence of side effects such as rash and joint pain associated with single-drug BRAF inhibitors. Large clinical trials have shown that the combined regimen can achieve a median PFS of more than 12 months in the treatment of patients with metastatic melanoma, and some patients can achieve long-term disease control, showing high clinical value.

During the use of canafenib, attention should be paid to liver function, blood pressure, electrocardiogram, skin reactions and other indicators. Patients should take medication under the guidance of a doctor, follow the dosage and medication schedule, and avoid increasing or decreasing the dosage on their own. For patients with poor tolerance or severe adverse reactions, temporary discontinuation or dose adjustment may be considered. Overall, Encorafenibacts as BRAFImportant targeted drugs for mutated tumors, with clear efficacy and good safety, provide patients with effective treatment options.

Reference materials:https://www.drugs.com/